Emerald Health Therapeutics’ Wholly Owned Subsidiary Northern Vine to Participate in Series of Cannabis Testing Seminars Hosted by Thermo Fisher Scientific
The seminar series will provide information to scientists establishing new cannabis testing laboratory or scaling-up operations. The series includes four stops in
“With nationwide legalization on the horizon, I’m honored to participate in this seminar series to share insights into how to comply with updated testing regulations for the Canadian cannabis market,” said Dr. Thomson. “The upcoming legal marketplace will create new opportunities for laboratories, licensed producers, and start-ups. Through this series, we hope to support and prepare these organizations to produce reliable results and ensure every sample meets regulated safety standards.”
For more information on Thermo Fisher Scientific’s complete cannabis testing solutions for the legalized Canadian market, please visit www.thermofisher.com/CannabisTesting.
Please visit www.emeraldhealth.ca for more information or contact:
(800) 757 3536 Ext. #5
(800) 757 3536 Ext. #5
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.
Source: Emerald Health Therapeutics Inc.